Aplastic Anemia in HIV: Updates in Hematologic Oncology

Article · September 2024

CITATIONS
0

READS
7

1 author:

Emmanuel Ifeanyi Obeagu
Africa University
2,100 PUBLICATIONS **36,090** CITATIONS

SEE PROFILE

Elite Journal of Health Sciences. Volume 2 Issue 9(2024), Pp. 70-80

https://epjournals.com/journals/EJHS

Aplastic Anemia in HIV: Updates in Hematologic Oncology

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) in HIV-infected patients represents a significant challenge in hematologic oncology due to the interplay between viral-induced immunosuppression and bone marrow failure. This review provides an overview of recent updates in the management and understanding of AA within the context of HIV infection. We discuss the complex pathophysiology of AA in HIV-positive individuals, highlighting how HIV-related immune dysregulation and viral effects contribute to bone marrow failure. Advances in diagnostic approaches and therapeutic strategies are explored, focusing on innovative treatments and their implications for patient care. The review also addresses ongoing research and future directions, emphasizing the need for continued advancements in diagnosis and therapy to improve outcomes for this vulnerable patient population.

Keywords: *Aplastic anemia, HIV, hematologic oncology, immunosuppression, bone marrow failure*

Introduction

Aplastic anemia (AA) is a critical hematologic disorder characterized by the failure of the bone marrow to produce sufficient blood cells, leading to pancytopenia. This condition results from the destruction or suppression of hematopoietic stem cells, resulting in a profound reduction in the production of red blood cells, white blood cells, and platelets. In patients infected with HIV, AA presents additional complexities due to the interplay between the virus and the bone marrow microenvironment. HIV-induced immunosuppression and associated complications exacerbate the challenges in diagnosing and managing AA, making it a particularly challenging area within hematologic oncology.[1-5] The pathogenesis of AA in HIV-infected individuals involves a multifaceted interaction between the virus and the host's hematopoietic system. HIV can directly infect hematopoietic progenitor cells, leading to their dysfunction and apoptosis. Additionally, the chronic immune activation and inflammation associated with HIV infection contribute to bone marrow suppression and impaired hematopoiesis. The interplay between HIV-induced immune

dysregulation and the resulting bone marrow environment creates a complex scenario where the mechanisms underlying AA are not fully understood, but involve both direct viral effects and indirect immune-mediated damage.[6-10] Recent advancements in diagnostic technologies have significantly enhanced the ability to identify and characterize AA in HIV-positive patients. Traditional diagnostic methods such as bone marrow biopsy and peripheral blood analysis are complemented by newer techniques including molecular diagnostics and advanced imaging. These innovations have improved the accuracy of diagnosing AA and distinguishing it from other causes of bone marrow failure. Enhanced diagnostic capabilities are crucial for tailoring treatment strategies to individual patient needs, particularly in the context of HIV infection where comorbidities and treatment interactions further complicate diagnosis.[11-15]

Management of AA in HIV-infected patients has evolved with the introduction of new therapeutic options. Traditional immunosuppressive therapies, such as anti-thymocyte globulin (ATG) and cyclosporine, remain central to treatment, but recent developments have introduced novel agents and combination therapies that offer new possibilities. Drugs like eltrombopag, which stimulate hematopoiesis, and targeted therapies that modulate the immune response have shown promise in clinical trials. These advancements provide additional tools for managing AA, offering hope for improved outcomes in patients whose condition is complicated by HIV.[16-20] Treating AA in HIV-positive patients involves addressing several unique challenges. The presence of HIV introduces concerns regarding drug interactions between antiretroviral therapies and hematologic treatments, which can impact the efficacy and safety of treatment regimens. Furthermore, the increased risk of infections in immunocompromised patients necessitates careful management to prevent and address complications. These challenges require a multidisciplinary approach, integrating the expertise of hematologists, infectious disease specialists, and other healthcare providers to optimize patient care.[21-25]

HIV and Aplastic Anemia Pathophysiology

Aplastic anemia (AA) in the context of HIV infection involves a complex interplay of viral effects, immune dysregulation, and bone marrow dysfunction. HIV can directly infect hematopoietic progenitor cells within the bone marrow. The virus primarily targets CD4+ T lymphocytes, but it can also infect other cells, including those involved in hematopoiesis. Infection of these progenitor cells can lead to their apoptosis or impaired function, disrupting normal hematopoiesis and contributing to the development of AA. This direct viral invasion can compromise the bone marrow's ability to produce adequate numbers of blood cells, leading to the clinical manifestations of AA.[27-30] HIV-induced immune dysregulation plays a significant role in the pathogenesis of AA. The chronic immune activation associated with HIV infection can lead to the production of autoantibodies and the activation of immune cells that attack bone marrow progenitor cells. This immune-mediated destruction contributes to the suppression of hematopoiesis and the development of AA. Elevated levels of pro-inflammatory cytokines and immune cell infiltration in the bone marrow further exacerbate this suppression, creating a hostile environment for hematopoietic stem cells.[31-35] While antiretroviral therapy (ART) is crucial for managing HIV infection, certain ART drugs can have hematologic side effects that impact bone marrow function. Drugs such as zidovudine (AZT) and other nucleoside reverse transcriptase inhibitors have been associated with bone marrow suppression, which can contribute to or worsen AA. Balancing the

efficacy of ART with the need to manage hematologic complications is a critical aspect of care for HIV-infected patients with AA.[36-40]

HIV-infected patients often have comorbid conditions that can further complicate AA. These comorbidities include opportunistic infections, malignancies, and other systemic illnesses that impact bone marrow function. Additionally, HIV-related conditions such as HIV-associated lymphomas or other malignancies can directly affect the bone marrow and contribute to the development of AA. Managing these comorbidities is essential for providing comprehensive care and improving outcomes in this patient population.[41-45] Recent research suggests that genetic and epigenetic factors may also play a role in the development of AA in HIV-infected individuals. Genetic variations affecting immune responses and bone marrow function could influence susceptibility to AA. Epigenetic modifications, such as DNA methylation and histone modifications, may alter gene expression related to hematopoiesis and immune regulation, contributing to the pathogenesis of AA in the context of HIV.[46-50] The bone marrow microenvironment in HIV-infected patients can be altered due to viral infection and immune dysregulation. Changes in the bone marrow niche, including alterations in cytokine levels and cellular interactions, can impact hematopoietic stem cell function and contribute to AA. HIV-infected patients with AA may also experience interactions with other hematologic disorders, such as anemia of chronic disease or HIV-related thrombocytopenia. These overlapping conditions can complicate the diagnosis and management of AA, making it essential to differentiate between these disorders and tailor treatment approaches accordingly.[51-55]

Advancements in Diagnostic Approaches

The diagnosis of aplastic anemia (AA) in HIV-infected patients has benefited from significant advancements in diagnostic technologies and methodologies. These innovations have improved the accuracy and speed of diagnosis, allowing for better characterization of the disease and more effective management strategies. Bone marrow biopsy remains a cornerstone in diagnosing AA, but recent advancements have refined this technique. Improvements in imaging-guided biopsy techniques, such as ultrasound or computed tomography (CT)-guided biopsies, enhance the precision of sampling and reduce complications. Additionally, advances in immunohistochemistry and molecular cytogenetics applied to bone marrow samples allow for more detailed analysis of marrow pathology and the identification of dysplastic changes or other abnormalities that may mimic or complicate AA.[56-60] Flow cytometry has become an invaluable tool in the diagnosis and characterization of AA. This technique allows for the detailed analysis of cell populations and the detection of abnormal cell phenotypes that may indicate underlying conditions. In AA, flow cytometry can help differentiate between various causes of bone marrow failure, such as malignancies or dysplastic syndromes, by analyzing surface markers and cellular characteristics. Advances in multi-parameter flow cytometry enable more comprehensive profiling of hematopoietic cells and their progenitors. The integration of molecular diagnostics has revolutionized the approach to diagnosing AA. Genetic testing for mutations and chromosomal abnormalities can provide critical insights into the etiology of AA. Techniques such as next-generation sequencing (NGS) allow for the comprehensive analysis of gene mutations, copy

number variations, and epigenetic alterations associated with AA. In HIV-infected patients, these tests can help distinguish between primary AA and secondary causes related to HIV or its treatments.[61-65]

Nucleic acid testing (NAT) has enhanced the ability to detect viral infections and assess the impact of HIV on hematopoiesis. NAT can identify low-level viral replication or latent infection that may contribute to bone marrow suppression. Additionally, NAT can help monitor the efficacy of antiretroviral therapy and its potential effects on hematologic parameters. This approach is particularly useful for managing HIV-infected patients with AA, as it allows for real-time monitoring of viral loads and potential treatment-related effects. Imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have become increasingly important in the evaluation of bone marrow disorders. MRI can provide detailed information about marrow infiltration, fibrosis, and other structural abnormalities. PET scans can help identify areas of increased metabolic activity or malignancy that may complicate AA. These imaging modalities are valuable for assessing disease progression and guiding treatment decisions.[66-70]

Proteomic and metabolomic analyses offer new avenues for understanding the molecular changes associated with AA. These approaches involve the comprehensive profiling of proteins and metabolites in blood or bone marrow samples. By identifying specific biomarkers associated with AA in HIV-infected patients, these techniques can enhance diagnostic accuracy and provide insights into disease mechanisms. They also hold potential for developing new diagnostic biomarkers and therapeutic targets. Artificial intelligence (AI) and machine learning algorithms are increasingly being applied to diagnostic processes in hematology. These technologies can analyze large datasets from various diagnostic tests, including imaging, flow cytometry, and genetic profiling, to identify patterns and predict disease outcomes. AI-driven tools can assist in the early detection of AA, stratify patients based on risk, and guide personalized treatment approaches.[71-75] The integration of genomics, proteomics, transcriptomics, and metabolomics data—known as multi-omics approaches—provides a comprehensive view of AA pathology. By combining data from various omics platforms, researchers and clinicians can gain a more holistic understanding of the disease and its interactions with HIV. This integrative approach facilitates the identification of novel biomarkers, therapeutic targets, and personalized treatment strategies.[76-77]

Innovative Therapeutic Strategies

The management of aplastic anemia (AA) in HIV-infected patients requires a multifaceted approach due to the complex interplay between the virus and the disease. Innovative therapeutic strategies are essential to improve outcomes and address the unique challenges posed by this dual diagnosis. Recent advancements in treatment modalities offer new hope for patients, focusing on both direct and indirect ways to manage AA in the context of HIV infection. Traditional immunosuppressive therapies, such as antithymocyte globulin (ATG) and cyclosporine, remain foundational in treating AA. However, recent innovations have introduced more targeted approaches to modulate the immune system with fewer side effects. For instance, the development of monoclonal antibodies that target specific immune pathways involved in AA has shown promise. Drugs such as alemtuzumab, which targets CD52-positive lymphocytes, and other

monoclonal antibodies that selectively modulate T-cell activity, offer more precise immunosuppressive effects and may improve patient outcomes.[78-83] Eltrombopag, a thrombopoietin receptor agonist, has emerged as a significant advancement in the treatment of AA. By stimulating megakaryocyte proliferation and enhancing platelet production, eltrombopag can improve hematopoiesis and address thrombocytopenia in AA patients. Research into the use of eltrombopag in combination with traditional immunosuppressive therapies or other novel agents is ongoing. Additionally, other hematopoietic growth factors and stimulators are being explored to enhance red blood cell and white blood cell production, offering potential benefits for AA management in HIV-infected individuals.[84-85]

Gene therapy and cellular therapies represent cutting-edge approaches to treating AA. Advances in gene editing technologies, such as CRISPR/Cas9, have the potential to correct genetic mutations associated with AA and restore normal hematopoiesis. Cellular therapies, including stem cell transplantation and ex vivo expansion of hematopoietic stem cells, offer the possibility of reconstituting healthy bone marrow. In the context of HIV, these therapies may need to be combined with antiretroviral strategies to address the underlying viral infection and prevent complications. For HIV-infected patients with AA, optimizing antiretroviral therapy is crucial to managing both the viral infection and its impact on bone marrow function. New classes of antiretroviral agents, including integrase inhibitors and entry inhibitors, offer potent viral suppression with fewer side effects. Combination therapies that target multiple aspects of HIV replication and immune activation can help reduce viral load and improve immune function, potentially alleviating some of the factors contributing to AA. Personalized approaches to antiretroviral therapy, guided by genetic and virologic factors, are being developed to enhance efficacy and minimize adverse effects.[86-87]

Recent research has focused on strategies to modulate the bone marrow microenvironment to support hematopoiesis. This includes targeting cytokine signaling pathways and using agents that enhance the supportive interactions between hematopoietic stem cells and the bone marrow niche. For instance, drugs that inhibit pro-inflammatory cytokines or promote the health of bone marrow stromal cells may help create a more favorable environment for hematopoiesis in AA patients. The integration of multiple therapeutic modalities, tailored to individual patient profiles, represents a promising approach to managing AA in HIV-infected patients. Combination therapies that blend immunosuppressive agents, hematopoietic stimulators, and targeted antiviral drugs offer a comprehensive approach to addressing both the hematologic and infectious aspects of the disease. Personalized medicine, guided by genetic, proteomic, and clinical factors, enables the development of customized treatment plans that optimize efficacy and minimize side effects. The identification of novel biomarkers associated with AA and HIV can facilitate early diagnosis and intervention. Biomarkers that predict disease progression, response to treatment, and risk of complications can guide therapeutic decisions and improve patient management. Research into the use of biomarkers for monitoring treatment response and disease activity is ongoing, with the goal of developing more effective and responsive treatment strategies. Innovative strategies in supportive care are essential for managing AA in HIV-infected patients. This includes advanced supportive measures such as growth factor support, prophylactic antibiotics, and transfusion strategies to manage

anemia, thrombocytopenia, and infections. Optimizing supportive care can help mitigate the impact of AA and improve overall patient outcomes.[83-87]

Conclusion

The management of aplastic anemia (AA) in HIV-infected patients presents a multifaceted challenge that demands innovative and integrated therapeutic strategies. Advances in diagnostic techniques, such as enhanced bone marrow biopsy methods, molecular diagnostics, and multi-omics approaches, have significantly improved the ability to accurately diagnose and characterize AA. These advancements enable a better understanding of the disease mechanisms and guide the development of tailored treatment strategies. Innovative therapeutic approaches, including targeted immunosuppressive therapies, novel hematopoietic stimulators, and gene and cellular therapies, offer promising avenues for managing AA. The integration of these therapies with optimized antiretroviral treatment and supportive care can address both the hematologic and infectious aspects of the disease. Emerging research into biomarkers, combination therapies, and personalized medicine holds the potential to further refine treatment strategies and improve patient outcomes.

References

1. Furlong E, Carter T. Aplastic anaemia: Current concepts in diagnosis and management. Journal of paediatrics and child health. 2020;56(7):1023-1028.
2. Chichetto NE, Polanka BM, So-Armah KA, Sung M, Stewart JC, Koethe JR, Edelman EJ, Tindle HA, Freiberg MS. Contribution of behavioral health factors to non-AIDS-related comorbidities: an updated review. Current HIV/AIDS Reports. 2020; 17:354-372.
3. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV, 2024; 2(1): 65-78
4. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
5. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 46-58
6. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(1):21-31
7. Obeagu EI, GU Obeagu. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health, 2024; 2 (1): 8-22
8. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com. 2024;12(01).
9. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine, 2024;2(1): 35-46
10. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology, 2024; 2(1): 34-46

11. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15
12. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science, 2024; 2(1): 33-42
13. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64
14. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology, 2024; 2(1): 1-13
15. Felker-Kantor EA, Wallace ME, Madkour AS, Duncan DT, Andrinopoulos K, Theall K. HIV stigma, mental health, and alcohol use disorders among people living with HIV/AIDS in New Orleans. Journal of urban health. 2019; 96:878-888.
16. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Asian J Dental Health Sci 2024;4(1):38-44. Available from: http://ajdhs.com/index.php/journal/article/view/63
17. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV, 2024; 2(2): 1-17
18. Obeagu EI, Obeagu GU.Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health, 2024; 2 (1): 22-34
19. Skalski LM, Sikkema KJ, Heckman TG, Meade CS. Coping styles and illicit drug use in older adults with HIV/AIDS. Psychology of Addictive Behaviors. 2013;27(4):1050.
20. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine, 2024; 2(2):104-115
21. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS spread: impact of religious leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
22. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
23. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.
24. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
25. Hill K, Kuo I, Shenoi SV, Desruisseaux MS, Springer SA. Integrated care models: HIV and substance use. Current HIV/AIDS Reports. 2023;20(5):286-295.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
27. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

Citation: Obeagu EI. Aplastic Anemia in HIV: Updates in Hematologic Oncology. Elite Journal of Health Science, 2024; 2(9): 70-80

28. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci [Internet]. 2023 Jun. 15 [cited 2024 Sep. 7];3(2):7-14. Available from: http://ajdhs.com/index.php/journal/article/view/39
29. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
30. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
31. Alum EU, Obeagu EI, Ugwu OP, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine. 2023 Oct 13;102(41):e35673.
32. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
33. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
34. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
35. Goodwin M. Black markets: the supply and demand of body parts. Cambridge University Press; 2006.
36. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
37. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
38. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
39. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
40. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda . Elite Journal of Medicine, 2024; 2(1): 1-16
41. Mandania EW. Haematological and Immunological Abnormalities in People Living With HIV: A Review. Journal of Medical and Biomedical Laboratory Sciences Research. 2024;4(1).
42. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
43. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.

44. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26
45. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
46. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73
47. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
48. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Applied Sciences (NIJBAS). 2023;3(3).
49. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
50. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
51. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
52. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
53. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20-35
54. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
55. American Psychiatric Association. Practice guideline for the treatment of patients with HIV/AIDS. American Psychiatric Pub; 2000.
56. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
57. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
58. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
59. Sukumaran RK. Long-Term Follow-Up and Chronic Complications. Contemporary Bone Marrow Transplantation. 2021:641-665.
60. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24

Citation: Obeagu EI. Aplastic Anemia in HIV: Updates in Hematologic Oncology. Elite Journal of Health Science, 2024; 2(9): 70-80

61. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
62. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
63. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
64. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
65. Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M. Stigma, disclosure, coping, and medication adherence among people living with HIV/AIDS in Northern Tanzania. AIDS patient care and STDs. 2014;28(2):98-105.
66. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
67. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
68. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
69. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
70. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
71. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
72. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
73. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
74. Banerjee N, Goodman ZT, McIntosh R, Ironson G. Cognition, coping, and psychological distress in HIV. AIDS and Behavior. 2022;26(4):1074-1083.
75. Grau LE, Griffiths-Kundishora A, Heimer R, Hutcheson M, Nunn A, Towey C, Stopka TJ. Barriers and facilitators of the HIV care continuum in Southern New England for people with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers. Addiction science & clinical practice. 2017; 12:1-4.
76. Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. BMC public health. 2018; 18:1-8.
77. Li H, Wu X, Shen J, Lou S. Perspective and experience of patients with aplastic anemia on medication adherence. Patient preference and adherence. 2023:2215-2225.

78. Beichler H, Grabovac I, Dorner TE. Integrated care as a model for interprofessional disease management and the benefits for people living with HIV/AIDS. International Journal of Environmental Research and Public Health. 2023;20(4):3374.
79. Rajabiun S, Tryon J, Feaster M, Pan A, McKeithan L, Fortu K, Cabral HJ, Borne D, Altice FL. The influence of housing status on the HIV continuum of care: results from a multisite study of patient navigation models to build a medical home for people living with HIV experiencing homelessness. American Journal of Public Health. 2018;108(S7):S539-45.
80. Dale SK, Safren SA. Striving towards empowerment and medication adherence (STEP-AD): a tailored cognitive behavioral treatment approach for black women living with HIV. Cognitive and Behavioral Practice. 2018;25(3):361-376.
81. Ngcobo S, Scheepers S, Mbatha N, Grobler E, Rossouw T. Roles, barriers, and recommendations for community health workers providing community-based HIV Care in Sub-Saharan Africa: a review. AIDS Patient Care and STDs. 2022;36(4):130-144.
82. Obeagu EI, Ogu RIO, Ngwoke AO. Psychosocial Impact of Aplastic Anemia Diagnosis in HIV Patients: A Narrative Review. Elite Journal of Public Health, 2024; 2 (7): 35-46
83. Obeagu EI, Akinleye CA. Stabilizing Hemoglobin Levels: A Vital Aspect of Blood Transfusions in HIV Management. *Elite Journal of Haematology, 2024; 2(9):* 1-8
84. Obeagu EI, Akinleye CA. Promoting Fertility: Blood Transfusions and Reproductive Health in HIV-Positive Individuals. *Elite Journal of Haematology, 2024; 2(9):* 9-16
85. Obeagu EI, Akinleye CA. Minimizing Treatment-Related Depression: Blood Transfusions and Mental Health Support in HIV Care. Elite Journal of Public Health, 2024; 2 (7): 16-24
86. Obeagu EI, Akinleye CA. Promoting Social Integration: Blood Transfusions and Improved Social Well-being in HIV Patients. Elite Journal of Public Health, 2024; 2 (7): 25-34
87. Obeagu EI, Akinleye CA. Optimizing Physical Endurance: Blood Transfusions in HIV and the Improvement of Exercise Capacity. Elite Journal of Medicine, 2024; 2(9): 1-9